Swelife conducted an interview with our Chief Medical Officer and co-founder Johan Hartman
Swelife conducted an interview with our Chief Medical Officer and co-founder Johan Hartman
Stratipath and Proscia Partnership Spotlighted in Pathology News
Stratipath and Proscia Partnership Spotlighted in Pathology News
First CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients
Stratipath, a global leader in AI-based precision diagnostic solutions, today announced that its AI software for prognostic risk stratification of breast cancers, Stratipath Breast, is now CE-IVD marked. This paves the way for clinical implementation in the European Union. Based on the analysis of digital histopathology whole slide images, stained with haematoxylin and eosin (H&E) the software provides novel decision support to clinicians and enables precision medicine for more patients.